NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
NEO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Neogenomics Inc. To summarize, we found that Neogenomics Inc ranked in the 3th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Neogenomics Inc, consider:
The compound growth rate in the free cash flow of Neogenomics Inc over the past 5.59 years is -0.01%; that's better than only 21.41% of cash flow producing equities in the Healthcare sector, where it is classified.
The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 11.92% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Neogenomics Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Neogenomics Inc? See ALC, AMPH, ARA, CSII, and ELAN.